| Literature DB >> 27811930 |
Francesc Artigas1,2,3, Esther Schenker4, Pau Celada1,2,3, Michael Spedding4, Laia Lladó-Pelfort1,2,3, Noemi Jurado1,2,3, Mercedes Núñez1,2,3, Noemi Santana1,2,3, Eva Troyano-Rodriguez1,2,3, Maurizio S Riga1,2,3, Hanna van den Munkhof1,2,3, Anna Castañé1,2,3, Hamdy Shaban5, Thérèse M Jay6, Anushree Tripathi6, Bill P Godsil6, Claude Sebban7, Jean Mariani7, Philippe Faure7, Samir Takkilah7, Zoe A Hughes8, Chester J Siok8, Mihaily Hajos8, Karsten Wicke9, Natalia Gass10, Wolfgang Weber-Fahr10, Alexander Sartorius10, Robert Becker10, Michael Didriksen11, Jesper F Bastlund11, Mark Tricklebank12, Céline Risterucci13, Andreas Meyer-Lindenberg10, Adam J Schwarz14.
Abstract
Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27811930 DOI： 10.1038/nrd.2016.205
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694